ASCO 2017: Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients

Chicago, IL (UroToday.com) In the last year, the S-TRAC randomized controlled trial (RCT) [1] demonstrated that patients receiving adjuvant sunitinib vs placebo for high risk renal cell carcinoma (RCC) have improved disease-free survival (DFS). Similarly, at the same session this morning, it was reported that patients treated with adjuvant pazopanib (800 mg) may also have improved DFS [2].

ASCO 2017: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT)

Chicago, IL (UroToday.com) On the heels of two randomized controlled trials (RCTs) recently published assessing adjuvant TKIs in the setting of patients treated with radical nephrectomy for locally advanced renal cell carcinoma (RCC) [1,2], Dr. Motzer and colleagues presented their findings at the 2017 ASCO annual meeting of another phase III RCT assessing adjuvant pazopanib vs placebo in these high risk patients.

ASCO 2017: Can Subgroup Analyses Identify Enrichment Strategies for Adjuvant RCC Studies?

Chicago, IL (UroToday.com) Dr. Daniel Heng from Calgary, Canada provided the discussant talk following presentation of Abstract 4507 (Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT) [1]) and Abstract 4508 (Phase III trial of adjuvant sunitinib in patients with high-risk RCC: Validation of the 16-gene Recurrence Score in stage III patients [2]) at ASCO 2017 genitourinary cancer oral abstract session.

ASCO 2017: Emerging VEGF-I/O Combinations: Efficacy and Toxicity

Chicago, IL (UroToday.com) Dr. Hans Hammers provided an excellent summary of abstracts 4504-4506 (Abstract 4504 TK Choueiri et al, Abstract 4505 MB Atkin et al, Abstract 4506 S. Chowdhury), all of which address emerging VEGF and immunotherapy combinations. The rationale for combination therapy can be traced back to the CheckMate 025 trial1, in which nivolumab was tested against everolimus as a second-line therapy for advanced RCC.

ASCO 2017: A phase I/II study to assess the safety and efficacy of pazopanib and pembrolizumab in patients with advanced renal cell carcinoma

Chicago, IL (UroToday.com) While the introduction of targeted therapies for the management of metastatic renal cell carcinoma drastically changed the landscape, they ultimately have been unable to provide a cure for patients with advanced renal cell carcinoma (aRCC). By providing progression-free survival (PFS), they have remained the mainstay of therapy for aRCC.

ASCO 2017: Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer

Chicago, IL (UroToday.com) It is known that second-line chemotherapies (chemo) for advanced urothelial carcinoma (UC) have limited clinical benefit (OS, 7-9 mo). Data from the open-label, phase 3 KEYNOTE-045 study (NCT02256436) showed significantly longer OS with pembro compared to 2nd line chemo (median, 10.3 v 7.4 mo; hazard ratio [HR], 0.73; P = 0.002) in recurrent advanced UC.

ASCO 2017: Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab in cisplatin-ineligible advanced urothelial cancer

Chicago, IL (UroToday.com) Comorbidities and renal impairment preclude many patients with advanced urothelial carcinoma (UC) from receiving chemotherapy. Initial results from the phase 2 KEYNOTE-052 (NCT02335424) trial suggested first-line Pembrolizumab (pembro) is active and safe in cisplatin-ineligible advanced UC patients. 
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe